Emricasan: Phase II data

Top-line data from 22 evaluable patients with portal hypertension and compensated liver cirrhosis predominantly due to non-alcoholic steatohepatitis (NASH) or HCV infection in an open-label, U.S. Phase

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE